Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,940 | 2 | 97.8% |
| Food and Beverage | $202.82 | 2 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Acceleron Pharma, Inc. | $7,040 | 1 | $0 (2020) |
| Eli Lilly and Company | $1,900 | 1 | $0 (2021) |
| Illumina, Inc. | $105.00 | 1 | $0 (2023) |
| Incyte Corporation | $97.82 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $105.00 | 1 | Illumina, Inc. ($105.00) |
| 2021 | $1,900 | 1 | Eli Lilly and Company ($1,900) |
| 2020 | $7,040 | 1 | Acceleron Pharma, Inc. ($7,040) |
| 2017 | $97.82 | 1 | Incyte Corporation ($97.82) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2023 | Illumina, Inc. | Oncology Testing (Device) | Food and Beverage | In-kind items and services | $105.00 | General |
| Category: Genetics | ||||||
| 09/02/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 11/04/2020 | Acceleron Pharma, Inc. | Reblozyl (Drug) | Consulting Fee | Cash or cash equivalent | $7,040.00 | General |
| Category: Hematology | ||||||
| 12/19/2017 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $97.82 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 862 | 1,010 | $235,185 | $34,111 |
| 2022 | 2 | 829 | 989 | $237,250 | $34,096 |
| 2021 | 12 | 1,317 | 1,818 | $347,735 | $63,728 |
| 2020 | 9 | 447 | 639 | $78,914 | $14,505 |
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0452 | Molecular pathology procedure; physician interpretation and report | Facility | 2023 | 370 | 421 | $86,305 | $17,111 | 19.8% |
| 88291 | Interpretation and report of genetic testing | Facility | 2023 | 492 | 589 | $148,880 | $17,001 | 11.4% |
| G0452 | Molecular pathology procedure; physician interpretation and report | Facility | 2022 | 362 | 423 | $84,600 | $17,128 | 20.2% |
| 88291 | Interpretation and report of genetic testing | Facility | 2022 | 467 | 566 | $152,650 | $16,968 | 11.1% |
| G0452 | Molecular pathology procedure; physician interpretation and report | Facility | 2021 | 455 | 534 | $77,940 | $22,450 | 28.8% |
| 88291 | Interpretation and report of genetic testing | Facility | 2021 | 386 | 438 | $108,470 | $13,817 | 12.7% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2021 | 83 | 421 | $56,835 | $10,826 | 19.0% |
| 88325 | Surgical pathology consultation and report, comprehensive | Facility | 2021 | 37 | 37 | $33,670 | $4,501 | 13.4% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2021 | 85 | 98 | $17,150 | $3,096 | 18.1% |
| 85097 | Bone marrow, smear interpretation | Facility | 2021 | 58 | 58 | $15,080 | $2,457 | 16.3% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2021 | 57 | 57 | $10,260 | $1,857 | 18.1% |
| 88360 | Microscopic genetic analysis of tumor, manual | Facility | 2021 | 31 | 39 | $9,750 | $1,473 | 15.1% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2021 | 18 | 18 | $7,200 | $1,358 | 18.9% |
| 88365 | Genetic sequencing localization, initial procedure | Facility | 2021 | 20 | 20 | $5,500 | $791.20 | 14.4% |
| 88311 | Preparation of tissue for examination by removing any calcium present | Facility | 2021 | 57 | 57 | $3,420 | $647.72 | 18.9% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2021 | 30 | 41 | $2,460 | $455.52 | 18.5% |
| G0452 | Molecular pathology procedure; physician interpretation and report | Facility | 2020 | 258 | 315 | $31,671 | $5,341 | 16.9% |
| 88341 | Special stained specimen slides to examine tissue | Facility | 2020 | 18 | 83 | $9,146 | $1,990 | 21.8% |
| 88360 | Microscopic genetic analysis of tumor | Facility | 2020 | 23 | 52 | $10,682 | $1,833 | 17.2% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2020 | 31 | 58 | $8,955 | $1,826 | 20.4% |
| 85097 | Bone marrow, smear interpretation | Facility | 2020 | 27 | 27 | $6,399 | $1,119 | 17.5% |
| 88342 | Tissue or cell analysis by immunologic technique | Facility | 2020 | 20 | 29 | $4,763 | $861.32 | 18.1% |
| 88381 | Preparation of specimen, manual | Facility | 2020 | 33 | 33 | $2,508 | $676.38 | 27.0% |
| 88365 | Analysis of genetic material | Facility | 2020 | 11 | 16 | $3,552 | $585.60 | 16.5% |
| 88311 | Preparation of tissue for examination by removing any calcium present | Facility | 2020 | 26 | 26 | $1,238 | $272.10 | 22.0% |
About Dr. Mark Ewalt, M.D
Dr. Mark Ewalt, M.D is a Cytopathology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/20/2009. The National Provider Identifier (NPI) number assigned to this provider is 1497998512.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Ewalt, M.D has received a total of $9,143 in payments from pharmaceutical and medical device companies, with $105.00 received in 2023. These payments were reported across 4 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($8,940).
As a Medicare-enrolled provider, Ewalt has provided services to 3,455 Medicare beneficiaries, totaling 4,456 services with total Medicare billing of $146,440. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Practice Information
- Specialty Cytopathology
- Other Specialties Hematology, Hematology
- Location New York, NY
- Active Since 04/20/2009
- Last Updated 08/25/2021
- Taxonomy Code 207ZC0500X
- Entity Type Individual
- NPI Number 1497998512
Products in Payments
- Reblozyl (Drug) $7,040
- Oncology Testing (Device) $105.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cytopathology Doctors in New York
Shabnam Jaffer, Md, MD
Cytopathology — Payments: $57,601
Maria Fiel, Md, MD
Cytopathology — Payments: $49,284
Andre Moreira, Md, MD
Cytopathology — Payments: $25,152
Wei Sun, M.d, M.D
Cytopathology — Payments: $854.37
Ami Patel, Md, MD
Cytopathology — Payments: $445.26
Guo-Xia Tong, M.d, M.D
Cytopathology — Payments: $439.69